Free Trial

JonesTrading's Rating of Intellia Therapeutics on 3/4/2026

On March 4, 2026, JonesTrading updated its outlook on Intellia Therapeutics (NASDAQ:NTLA) with the action "Upgrade", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from JonesTrading

DateCompanyAction
10/15/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Boost Price Target
10/8/2026
IPXG
Inflection Point
Initiated Coverage
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Lower Price Target
10/6/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Boost Price Target
10/6/2026
Geo Group Inc (The) stock logo
GEO
Geo Group
Reiterated Rating
10/1/2026
CTO Realty Growth, Inc. stock logo
CTO
CTO Realty Growth
Reiterated Rating
More Ratings From JonesTrading